June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Gene therapy for a mouse model of Achromatopsia
Author Affiliations & Notes
  • Shanta Sarfare
    Ophthalmology, University of Florida, Gainesville, FL
  • Seok-Hong Min
    Ophthalmology, University of Florida, Gainesville, FL
  • Sanford L Boye
    Ophthalmology, University of Florida, Gainesville, FL
  • Shannon Elizabeth Boye
    Ophthalmology, University of Florida, Gainesville, FL
  • William W Hauswirth
    Ophthalmology, University of Florida, Gainesville, FL
  • Christine Nichols Kay
    Ophthalmology, University of Florida, Gainesville, FL
  • Footnotes
    Commercial Relationships Shanta Sarfare, None; Seok-Hong Min, None; Sanford Boye, None; Shannon Boye, None; William Hauswirth, None; Christine Kay, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5469. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shanta Sarfare, Seok-Hong Min, Sanford L Boye, Shannon Elizabeth Boye, William W Hauswirth, Christine Nichols Kay; Gene therapy for a mouse model of Achromatopsia. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5469. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Achromatopsia is an autosomal recessive retinal disorder characterized by cone photoreceptor dysfunction with an incidence of 1:30,000. Mutations in the cone cyclic nucleotide gated cation channel beta (CNGB3) account for 50% of the incidence of achromatopsia. Although there is a Cngb3 knockout mouse, it is difficult to investigate cone function in this model, as cones comprise a very small proportion of the mouse retina. Mice lacking the Nrl gene have no rods, increased S-cones and enhanced cone function. In this study, we investigated the results of gene replacement therapy in a Cngb3/Nrl double knockout (DKO) mouse retina to more closely approximate the cone-dominant macula of achromatopsia patients.

Methods: One microliter viral vector AAV8 (Y733F)-Cngb3 (1 x1012 vector genomes/ml) where the Cngb3 gene is driven by the photoreceptor-specific IRBP/GNAT2 promoter, was injected in the subretinal space of 15 days old Cngb3/Nrl DKO mice. One eye was injected whereas the contralateral eye was the non-injected control.

Results: The treated eyes show increased photopic ERG and S-opsin mediated ERG b-wave amplitude responses compared to untreated fellow eyes up to 8 months post-injection. Administration of the AAV8-Cngb3 resulted in the preservation of S-opsin and cone transducin in the photoreceptor outer segments up to 3 months post-injection.

Conclusions: AAV-mediated gene delivery of CNGB3 results in long-term restoration of cone function in the Cngb3/Nrl DKO mouse. Ongoing studies include live OCT imaging and immunolocalization of other cone-specific markers in the treated mice. The Cngb3/Nrl DKO mice may serve as a useful model for developing and testing therapeutic strategies for human cone photoreceptor degenerative diseases.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.